Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 44, Issue 12

Issues

Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

Hugo Vanderstichele / Karen De Vreese / Kaj Blennow / Niels Andreasen
  • Neurotec, Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Christian Sindic / Adrian Ivanoiu / Harald Hampel / Katharina Bürger / Lucilla Parnetti / Alessia Lanari / Allesandro Padovani / Monica DiLuca / Miriam Bläser / Annika Ohrfelt Olsson / Hans Pottel / Frank Hulstaert / Eugeen Vanmechelen
Published Online: 2006-12-13 | DOI: https://doi.org/10.1515/CCLM.2006.258

Abstract

Background: Total tau (T-tau) and β-amyloid(1-42) (Aβ1-42) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult.

Methods: The analytical performance of the INNOTEST® PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Aβ1-42, for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study.

Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau181P) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau181P was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB.

Conclusions: P-tau181P quantification is a robust and reliable assay that may be useful in discriminating AD from DLB.

Clin Chem Lab Med 2006;44:1472–80.

Keywords: Alzheimer's disease; cerebrospinal fluid; dementia; diagnosis; performance; P-tau181P

References

  • 1.

    Wiltfang J, Esselman H, Maler JM, Bleich S, Hüther G, Kornhuber J. Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 2001; 47:65–71.CrossrefGoogle Scholar

  • 2.

    Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000; 33:95–130.CrossrefGoogle Scholar

  • 3.

    Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2:605–13.CrossrefGoogle Scholar

  • 4.

    Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109–16 (Erratum in Neurobiol Aging1998;19:285).Google Scholar

  • 5.

    Vanmechelen E, Van Kerschaver E, Blennow K, De Deyn PP, Galasko D, Parnetti L, et al. CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B, editors. Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. New York: Wiley, 2001;285–91.Google Scholar

  • 6.

    Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, van Kamp GJ, et al. Amyloid β(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004; 62:1580–4.CrossrefGoogle Scholar

  • 7.

    Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3:519–26.CrossrefGoogle Scholar

  • 8.

    Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin J-J, et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61:1828–34.CrossrefGoogle Scholar

  • 9.

    Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse M-A, Andreasen N, et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000; 7:245–58.CrossrefGoogle Scholar

  • 10.

    Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285:49–52.Google Scholar

  • 11.

    ISO 5725–2: Accuracy (trueness and precision) of measurement methods and results - Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method, Geneva: International Organization for Standardization, 1994.Google Scholar

  • 12.

    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939–44.CrossrefGoogle Scholar

  • 13.

    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113–24.CrossrefGoogle Scholar

  • 14.

    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–98.CrossrefGoogle Scholar

  • 15.

    Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52:1555–62.CrossrefGoogle Scholar

  • 16.

    Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J 1994; 301:871–7.Google Scholar

  • 17.

    Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70:624–30.CrossrefGoogle Scholar

  • 18.

    Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP Technology. Clin Chem 2005; 51:336–45.CrossrefGoogle Scholar

  • 19.

    Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesiel-czyk B, Neubert K, et al. Total tau protein, posphorylated tau (181p) protein, β-amyloid1-42, and β-amyloid1-40 in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 2006; 44:192–5.Google Scholar

  • 20.

    Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1:213–25.CrossrefGoogle Scholar

  • 21.

    Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004; 61:95–102.CrossrefGoogle Scholar

  • 22.

    Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects – a comparative CSF study. Neurology 2005; 65:1502–3.CrossrefGoogle Scholar

  • 23.

    Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59:1267–72.CrossrefGoogle Scholar

  • 24.

    Nägga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 2002; 14:183–90.CrossrefGoogle Scholar

  • 25.

    Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, de Bustos F, Zurdo JM, Alonso H, et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2005; 111:114–7.CrossrefGoogle Scholar

  • 26.

    Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003; 8:343–7.CrossrefGoogle Scholar

  • 27.

    Zetterberg H, Blennow K. Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results. Neurol Sci 2004; 25:301–2.Google Scholar

  • 28.

    Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci 2004; 23:115–22.CrossrefGoogle Scholar

  • 29.

    Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42. Arch Neurol 2003; 60:1202–6.Google Scholar

  • 30.

    Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005; 19:164–70.CrossrefGoogle Scholar

About the article

Corresponding author: Hugo Vanderstichele, PhD, Innogenetics, Industriepark Zwijnaarde 7, P.O. Box 4, 9052 Gent, Belgium Phone: +32-9-2410711, Fax: +32-9-2410907


Received: 2006-05-13

Accepted: 2006-09-14

Published Online: 2006-12-13

Published in Print: 2006-12-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 44, Issue 12, Pages 1472–1480, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2006.258.

Export Citation

©2006 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
[2]
Emmanuelle Duron, Jean-Sébastien Vidal, Dominique Grousselle, Audrey Gabelle, Sylvain Lehmann, Florence Pasquier, Luc Buée, Bernadette Allinquant, Susanna Schraen-Maschke, Christiane Baret, Anne-Sophie Rigaud, Olivier Hanon, and Jacques Epelbaum
Frontiers in Aging Neuroscience, 2018, Volume 10
[3]
Angela M. Sanford
Clinics in Geriatric Medicine, 2018
[4]
Karin Gmitterová, Joanna Gawinecka, Franc Llorens, Daniela Varges, Peter Valkovič, and Inga Zerr
European Archives of Psychiatry and Clinical Neuroscience, 2018
[5]
Oskar Hansson, Alvydas Mikulskis, Anne M. Fagan, Charlotte Teunissen, Henrik Zetterberg, Hugo Vanderstichele, Jose Luis Molinuevo, Leslie M. Shaw, Manu Vandijck, Marcel M. Verbeek, Mary Savage, Niklas Mattsson, Piotr Lewczuk, Richard Batrla, Sandra Rutz, Robert A. Dean, and Kaj Blennow
Alzheimer's & Dementia, 2018
[6]
Sylvain Lehmann, Constance Delaby, Guilaine Boursier, Cindy Catteau, Nelly Ginestet, Laurent Tiers, Aleksandra Maceski, Sophie Navucet, Claire Paquet, Julien Dumurgier, Eugeen Vanmechelen, Hugo Vanderstichele, and Audrey Gabelle
Frontiers in Aging Neuroscience, 2018, Volume 10
[7]
Sergio Bagnato, Maria Andriolo, Cristina Boccagni, Antonino Sant’Angelo, Maria Enza D’Ippolito, and Giuseppe Galardi
Brain Injury, 2018, Page 1
[8]
Yaping Liu, Tian Wang, Xiaojing He, Yanling Li, and Tian Wang
Biochemical and Biophysical Research Communications, 2017
[9]
Marcel Levy Nogueira, Dalila Samri, Stéphane Epelbaum, Simone Lista, Per Suppa, Lothar Spies, Harald Hampel, Bruno Dubois, and Marc Teichmann
Journal of Alzheimer's Disease, 2017, Page 1
[10]
Sudad Saman, WonHee Kim, Mario Raya, Yvonne Visnick, Suhad Miro, Sarmad Saman, Bruce Jackson, Ann C. McKee, Victor E. Alvarez, Norman C. Y. Lee, and Garth F. Hall
Journal of Biological Chemistry, 2012, Volume 287, Number 6, Page 3842
[11]
Suzanne J. Reid, Natasha E. Mckean, Kristen Henty, Erik Portelius, Kaj Blennow, Skye R. Rudiger, C. Simon Bawden, Renee R. Handley, Paul J. Verma, Richard L.M. Faull, Henry J. Waldvogel, Henrik Zetterberg, and Russell G. Snell
Neurobiology of Aging, 2017, Volume 58, Page 112
[12]
Douglas Galasko
Neurologic Clinics, 2017, Volume 35, Number 2, Page 325
[13]
Siddharth Ramanan, Leonardo Cruz de Souza, Noémie Moreau, Marie Sarazin, Antônio L. Teixeira, Zoe Allen, Henrique C. Guimarães, Paulo Caramelli, Bruno Dubois, Michael Hornberger, and Maxime Bertoux
Cortex, 2017, Volume 88, Page 8
[14]
R W Paterson, W E Heywood, A J Heslegrave, N K Magdalinou, U Andreasson, E Sirka, E Bliss, C F Slattery, J Toombs, J Svensson, P Johansson, N C Fox, H Zetterberg, K Mills, and J M Schott
Translational Psychiatry, 2016, Volume 6, Number 11, Page e952
[15]
Harmony Duclos, Vincent de La Sayette, Anne-Laure Bonnet, Armelle Viard, Francis Eustache, Béatrice Desgranges, Mickaël Laisney, and Maxime Bertoux
Journal of Alzheimer's Disease, 2016, Volume 55, Number 2, Page 459
[16]
Carla Abdelnour, Inger van Steenoven, Elisabet Londos, Frédéric Blanc, Bjørn Auestad, Milica G. Kramberger, Henrik Zetterberg, Brit Mollenhauer, Mercè Boada, and Dag Aarsland
Movement Disorders, 2016, Volume 31, Number 8, Page 1203
[17]
Olivier Bousiges, Benjamin Cretin, Thomas Lavaux, Nathalie Philippi, Barbara Jung, Sylvie Hezard, Camille Heitz, Catherine Demuynck, Aurelia Gabel, Catherine Martin-Hunyadi, and Frédéric Blanc
Journal of Alzheimer's Disease, 2016, Volume 51, Number 4, Page 1069
[18]
Lou Grangeon, Claire Paquet, Stephanie Bombois, Muriel Quillard-Muraine, Olivier Martinaud, Bertrand Bourre, Romain Lefaucheur, Gaël Nicolas, Julien Dumurgier, Emmanuel Gerardin, Mary Jan, Jean-Louis Laplanche, Katell Peoc’h, Jacques Hugon, Florence Pasquier, David Maltête, Didier Hannequin, and David Wallon
Journal of Alzheimer's Disease, 2016, Volume 51, Number 3, Page 905
[19]
Elena Piccoli, Giacomina Rossi, Tommaso Rossi, Giuseppe Pelliccioni, Ilaria D'Amato, Fabrizio Tagliavini, and Giuseppe Di Fede
Neurobiology of Aging, 2016, Volume 40, Page 192.e7
[20]
Masaki Kondo, Takuma Ohmichi, Mao Mukai, Jun Fujinami, Masanori Nakagawa, and Toshiki Mizuno
Rinsho Shinkeigaku, 2015, Volume 55, Number 5, Page 320
[21]
Sven Joubert, Natalina Gour, Eric Guedj, Mira Didic, Claude Guériot, Lejla Koric, Jean-Philippe Ranjeva, Olivier Felician, Maxime Guye, and Mathieu Ceccaldi
Cortex, 2016, Volume 74, Page 217
[22]
Giulia M. Sancesario and Sergio Bernardini
Critical Reviews in Clinical Laboratory Sciences, 2015, Volume 52, Number 6, Page 314
[23]
Sun Ah Park, Ju-Hee Kang, Eun-Suk Kang, Chang-Seok Ki, Jee Hoon Roh, Young Chul Youn, Seong Yoon Kim, and Sang Yun Kim
Journal of Clinical Neurology, 2015, Volume 11, Number 2, Page 132
[24]
Christopher D. Aluise, Renã A. Sowell, and D. Allan Butterfield
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008, Volume 1782, Number 10, Page 549
[25]
Sebastian Schade and Brit Mollenhauer
Alzheimer's Research & Therapy, 2014, Volume 6, Number 5-8
[26]
M.S. Heier, A. Skinningsrud, E. Paus, and K.M. Gautvik
Sleep Medicine, 2014, Volume 15, Number 6, Page 614
[27]
A. M. Fagan, C. Xiong, M. S. Jasielec, R. J. Bateman, A. M. Goate, T. L. S. Benzinger, B. Ghetti, R. N. Martins, C. L. Masters, R. Mayeux, J. M. Ringman, M. N. Rossor, S. Salloway, P. R. Schofield, R. A. Sperling, D. Marcus, N. J. Cairns, V. D. Buckles, J. H. Ladenson, J. C. Morris, and D. M. Holtzman
Science Translational Medicine, 2014, Volume 6, Number 226, Page 226ra30
[28]
Natalina Gour, Olivier Felician, Mira Didic, Lejla Koric, Claude Gueriot, Valérie Chanoine, Sylviane Confort-Gouny, Maxime Guye, Mathieu Ceccaldi, and Jean Philippe Ranjeva
Human Brain Mapping, 2014, Volume 35, Number 7, Page 2978
[29]
J-D Abraham, S Promé, N Salvetat, L Rubrecht, S Cobo, E du Paty, P Galéa, E Mathieu-Dupas, S Ranaldi, C Caillava, G-A Crémer, F Rieunier, P Robert, F Molina, D Laune, F Checler, and J Fareh
Translational Psychiatry, 2013, Volume 3, Number 7, Page e281
[30]
Suk Ling Ma and Linda Chiu Wa Lam
Clinical Psychopharmacology and Neuroscience, 2011, Volume 9, Number 2, Page 54
[31]
Leonardo Guzmán-Martínez, Gonzalo A. Farías, and Ricardo B. Maccioni
Archives of Medical Research, 2012, Volume 43, Number 8, Page 663
[32]
Kristen E. Funk and Jeff Kuret
International Journal of Alzheimer's Disease, 2012, Volume 2012, Page 1
[33]
Ulf Andreasson, Eugeen Vanmechelen, Leslie M Shaw, Henrik Zetterberg, and Hugo Vanderstichele
Biomarkers in Medicine, 2012, Volume 6, Number 4, Page 377
[34]
Hans Brunnström, Oskar Hansson, Henrik Zetterberg, Elisabet Londos, and Elisabet Englund
International Journal of Geriatric Psychiatry, 2013, Volume 28, Number 7, Page 738
[35]
Sébastien Ranaldi, Céline Caillava, Sylvie Promé, Laetitia Rubrecht, Sandra Cobo, Nicolas Salvetat, Emilie du Paty, Pascale Galea, Gudrun Aldrian, Dung Le Nguyen, Pierre Krolak-Salmon, Franck Molina, Daniel Laune, Frédéric Checler, Jeannette Fareh, and Jean-Daniel Abraham
Neurobiology of Aging, 2013, Volume 34, Number 2, Page 523
[36]
Christopher M. Acker, Stefanie K. Forest, Ray Zinkowski, Peter Davies, and Cristina d'Abramo
Neurobiology of Aging, 2013, Volume 34, Number 1, Page 338
[37]
Bengt Winblad, Niels Andreasen, Lennart Minthon, Annette Floesser, Georges Imbert, Thomas Dumortier, R Paul Maguire, Kaj Blennow, Joens Lundmark, Matthias Staufenbiel, Jean-Marc Orgogozo, and Ana Graf
The Lancet Neurology, 2012, Volume 11, Number 7, Page 597
[38]
F. Tabaraud, J. P. Leman, A. M. Milor, J. M. Roussie, G. Barrière, M. Tartary, F. Boutros-Toni, and M. Rigaud
Acta Neurologica Scandinavica, 2012, Volume 125, Number 6, Page 416
[39]
Namrta Sinha, Michael Firbank, and John T. O'Brien
International Journal of Geriatric Psychiatry, 2012, Volume 27, Number 5, Page 443
[40]
Ju-Hee Kang, Hugo Vanderstichele, John Q. Trojanowski, and Leslie M. Shaw
Methods, 2012, Volume 56, Number 4, Page 484
[42]
Gregory A. Jicha, Erin L. Abner, Frederick A. Schmitt, Richard J. Kryscio, Kathryn P. Riley, Gregory E. Cooper, Nancy Stiles, Marta S. Mendiondo, Charles D. Smith, Linda J. Van Eldik, and Peter T. Nelson
Neurobiology of Aging, 2012, Volume 33, Number 3, Page 622.e1
[43]
Ragnhild Skogseth, Tormod Fladby, Ezra Mulugeta, and Dag Aarsland
Tidsskrift for Den norske legeforening, 2011, Volume 131, Number 22, Page 2235
[44]
P. Krolak-Salmon, J. Seguin, A. Perret-Liaudet, V. Desestret, A. Vighetto, and M. Bonnefoy
La Revue de Médecine Interne, 2008, Volume 29, Number 10, Page 785
[45]
Lucilla Parnetti, Pietro Tiraboschi, Alessia Lanari, Maria Peducci, Chiara Padiglioni, Cataldo D'Amore, Laura Pierguidi, Nicola Tambasco, Aroldo Rossi, and Paolo Calabresi
Biological Psychiatry, 2008, Volume 64, Number 10, Page 850
[46]
Nathalie Le Bastard, Jean-Jacques Martin, Eugeen Vanmechelen, Hugo Vanderstichele, Peter Paul De Deyn, and Sebastiaan Engelborghs
Neurobiology of Aging, 2010, Volume 31, Number 11, Page 1867
[47]
Kenji Wada-Isoe, Michio Kitayama, Kazuhiro Nakaso, and Kenji Nakashima
Journal of the Neurological Sciences, 2007, Volume 260, Number 1-2, Page 33
[48]
Joshua A Sonnen, Kathleen S Montine, Joseph F Quinn, Jeffrey A Kaye, John CS Breitner, and Thomas J Montine
The Lancet Neurology, 2008, Volume 7, Number 8, Page 704
[49]
Karen Koopman, Nathalie Le Bastard, Jean-Jacques Martin, Guy Nagels, Peter P. De Deyn, and Sebastiaan Engelborghs
Neurochemistry International, 2009, Volume 55, Number 4, Page 214
[50]
Elizabeta B. Mukaetova-Ladinska, Rachael Monteith, and Elaine K. Perry
International Journal of Alzheimer's Disease, 2010, Volume 2010, Page 1
[51]
L. Koric, O. Felician, and M. Ceccaldi
Revue Neurologique, 2011, Volume 167, Number 6-7, Page 474
[52]
Argonde C. van Harten, Maartje I. Kester, Pieter-Jelle Visser, Marinus A. Blankenstein, Yolande A.L. Pijnenburg, Wiesje M. van der Flier, and Philip Scheltens
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 3
[53]
Jean-Daniel Abraham, Sophie Calvayrac-Pawlowski, Sandra Cobo, Nicolas Salvetat, Guillaume Vicat, Laurence Molina, Jacques Touchon, Bernard-François Michel, Franck Molina, Jean-Michel Verdier, Jeannette Fareh, and Chantal Mourton-Gilles
Biomarkers, 2011, Volume 16, Number 2, Page 161
[54]
Alex E. Roher, Chera L. Maarouf, Lucia I. Sue, Yiran Hu, Jeffrey Wilson, and Thomas G. Beach
Biomarkers, 2009, Volume 14, Number 7, Page 493
[55]
Daniëlle de Jong, Berry P.H. Kremer, Marcel G.M. Olde Rikkert, and Marcel M. Verbeek
Clinical Chemical Laboratory Medicine, 2007, Volume 45, Number 11
[56]
Hayrettin Tumani, Charlotte Teunissen, Sigurd Süssmuth, Markus Otto, Albert C Ludolph, and Johannes Brettschneider
Expert Review of Molecular Diagnostics, 2008, Volume 8, Number 4, Page 479
[57]
Nicolas Sergeant, Alexis Bretteville, Malika Hamdane, Marie-Laure Caillet-Boudin, Pierre Grognet, Stephanie Bombois, David Blum, André Delacourte, Florence Pasquier, Eugeen Vanmechelen, Susanna Schraen-Maschke, and Luc Buée
Expert Review of Proteomics, 2008, Volume 5, Number 2, Page 207
[58]
Eric Siemers, Ronald B DeMattos, Patrick C May, and Robert A Dean
Biomarkers in Medicine, 2010, Volume 4, Number 1, Page 81
[59]
Susanna Schraen-Maschke, Nicolas Sergeant, Claire-Marie Dhaenens, Stéphanie Bombois, Vincent Deramecourt, Marie-Laure Caillet-Boudin, Florence Pasquier, Claude-Alain Maurage, Bernard Sablonnière, Eugeen Vanmechelen, and Luc Buée
Biomarkers in Medicine, 2008, Volume 2, Number 4, Page 363
[61]
Lejla Koric, Olivier Felician, Eric Guedj, Anne Michele Hubert, Julien Mancini, Jose Boucraut, and Mathieu Ceccaldi
Alzheimer Disease & Associated Disorders, 2010, Page 1
[62]
Harald Hampel, Richard Frank, Karl Broich, Stefan J. Teipel, Russell G. Katz, John Hardy, Karl Herholz, Arun L. W. Bokde, Frank Jessen, Yvonne C. Hoessler, Wendy R. Sanhai, Henrik Zetterberg, Janet Woodcock, and Kaj Blennow
Nature Reviews Drug Discovery, 2010, Volume 9, Number 7, Page 560
[63]
Min Shi, Bertrand R. Huber, and Jing Zhang
Brain Pathology, 2010, Volume 20, Number 3, Page 660
[64]
Kaj Blennow, Harald Hampel, Michael Weiner, and Henrik Zetterberg
Nature Reviews Neurology, 2010, Volume 6, Number 3, Page 131
[65]
J. Hort, A. Bartos, T. Pirttilä, and P. Scheltens
European Journal of Neurology, 2010, Volume 17, Number 1, Page 90
[66]
Yaroslau Compta, María J. Martí, Naroa Ibarretxe-Bilbao, Carme Junqué, Francesc Valldeoriola, Esteban Muñoz, Mario Ezquerra, Jose Ríos, and Eduardo Tolosa
Movement Disorders, 2009, Volume 24, Number 15, Page 2203
[67]
Brit Mollenhauer and Claudia Trenkwalder
Movement Disorders, 2009, Volume 24, Number 10, Page 1411
[68]
F. Deisenhammer, R. Egg, G. Giovannoni, B. Hemmer, A. Petzold, F. Sellebjerg, C. Teunissen, and H. Tumani
European Journal of Neurology, 2009, Volume 16, Number 6, Page 760
[69]
Klaus Tatsch
European Journal of Nuclear Medicine and Molecular Imaging, 2008, Volume 35, Number S1, Page 51
[70]
Dag Aarsland, Martin Kurz, Mona Beyer, Kolbjørn Bronnick, Sabine Piepenstock Nore, and Clive Ballard
Dementia and Geriatric Cognitive Disorders, 2008, Volume 25, Number 3, Page 195
[71]
International Journal of Geriatric Psychiatry, 2007, Volume 22, Number 9, Page 937
[72]
O. Sobek, P. Adam, and J. Svatonova
European Journal of Neurology, 2007, Volume 14, Number 6, Page e14

Comments (0)

Please log in or register to comment.
Log in